UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Psoriasis: epidemiology, clinical features, and quality of life

Annals of the rheumatic diseases, 2005-03, Vol.64 (suppl 2), p.ii18-ii23

2005

Volltextzugriff (PDF)

Definition of treatment goals for moderate to severe psoriasis: a European consensus

ARCHIVES OF DERMATOLOGICAL RESEARCH, 2011-01, Vol.303 (1), p.1-10

2011

Volltextzugriff (PDF)

Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial

Gut, 2006-04, Vol.55 (4), p.505-509

2006

Volltextzugriff (PDF)

Improvements in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: the CRYSTEL study

Journal of the European Academy of Dermatology and Venereology, 2009-12, Vol.23 (12), p.1374-1382

2009

Volltextzugriff (PDF)

Single-Nucleotide Polymorphisms of Vascular Endothelial Growth Factor in Psoriasis of Early Onset

Journal of investigative dermatology, 2004-01, Vol.122 (1), p.209-215

2004

Volltextzugriff (PDF)

Altered claudin expression is a feature of chronic plaque psoriasis

The Journal of pathology, 2007-08, Vol.212 (4), p.450-458

2007

Volltextzugriff (PDF)

Genetic Analysis of PSORS1 Distinguishes Guttate Psoriasis and Palmoplantar Pustulosis

Journal of investigative dermatology, 2003-04, Vol.120 (4), p.627-632

2003

Volltextzugriff (PDF)

Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence

Journal of investigative dermatology, 2013-02, Vol.133 (2), p.377-385

2013

Volltextzugriff (PDF)

Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials

The New England journal of medicine, 2014-07, Vol.371 (4), p.326-338

2014

Volltextzugriff (PDF)

Systematic review examining changes over time and variation in the incidence and prevalence of psoriasis by age and gender

British journal of dermatology (1951), 2021-02, Vol.184 (2), p.243-258

2021

Volltextzugriff (PDF)

Incidence, prevalence and mortality of patients with psoriasis: a U.K. population‐based cohort study

British journal of dermatology (1951), 2017-03, Vol.176 (3), p.650-658

2017

Volltextzugriff (PDF)

The EGALITY study: a confirmatory, randomized, double‐blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate‐to‐severe chronic plaque‐type psoriasis

British journal of dermatology (1951), 2017-04, Vol.176 (4), p.928-938

2017

Volltextzugriff (PDF)

Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)

British journal of dermatology (1951), 2020-08, Vol.183 (2), p.294-302

2020

Volltextzugriff (PDF)

The global state of psoriasis disease epidemiology: a workshop report

British journal of dermatology (1951), 2017-07, Vol.177 (1), p.e4-e7

2017

Volltextzugriff (PDF)

Reduction in skin cancer diagnosis, and overall cancer referrals, during the COVID‐19 pandemic

British journal of dermatology (1951), 2020-10, Vol.183 (4), p.792-794

2020

Volltextzugriff (PDF)

Psoriasis treat to target: defining outcomes in psoriasis using data from a real‐world, population‐based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR)

British journal of dermatology (1951), 2020-05, Vol.182 (5), p.1158-1166

2020

Volltextzugriff (PDF)

Clinical characteristics, symptoms and burden of psoriasis and atopic dermatitis in adults

British journal of dermatology (1951), 2020-07, Vol.183 (1), p.128-138

2020

Volltextzugriff (PDF)

Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta‐analysis of randomized controlled trials

British journal of dermatology (1951), 2017-04, Vol.176 (4), p.890-901

2017

Volltextzugriff (PDF)

Professor Lionel Fry (1933–2021)

British journal of dermatology (1951), 2021-07, Vol.185 (1), p.237-238

Griffiths, C.E.M.

2021

Volltextzugriff (PDF)

A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 24‐week efficacy and safety results from a randomized, double‐blinded trial

British journal of dermatology (1951), 2021-06, Vol.184 (6), p.1047-1058

2021

Volltextzugriff (PDF)

Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double‐blinded, controlled studies (UNCOVER‐1, UNCOVER‐2, UNCOVER‐3)

British journal of dermatology (1951), 2018-03, Vol.178 (3), p.674-681

2018

Volltextzugriff (PDF)

Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up

British journal of dermatology (1951), 2013-04, Vol.168 (4), p.844-854

2013

Volltextzugriff (PDF)

Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study

British journal of dermatology (1951), 2019-05, Vol.180 (5), p.1069-1076

2019

Volltextzugriff (PDF)

The promise and challenges of cell therapy for psoriasis

British journal of dermatology (1951), 2021-11, Vol.185 (5), p.887-898

2021

Volltextzugriff (PDF)

The risk of malignancy in patients with secukinumab‐treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow‐up

British journal of dermatology (1951), 2021-11, Vol.185 (5), p.935-944

2021

Volltextzugriff (PDF)

1 – 25 von 460

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(434)
Mit Volltextzugriff
(412)

Publikationsform

Artikel
(455)
Tagungsberichte
(5)

Sprache

Englisch
(460)
Chinesisch
(5)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Psoriasis: epidemiology, clinical features, and quality of life

Definition of treatment goals for moderate to severe psoriasis: a European consensus

Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial

Improvements in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: the CRYSTEL study

Single-Nucleotide Polymorphisms of Vascular Endothelial Growth Factor in Psoriasis of Early Onset

Altered claudin expression is a feature of chronic plaque psoriasis

Genetic Analysis of PSORS1 Distinguishes Guttate Psoriasis and Palmoplantar Pustulosis

Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence

Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials

Systematic review examining changes over time and variation in the incidence and prevalence of psoriasis by age and gender

Incidence, prevalence and mortality of patients with psoriasis: a U.K. population‐based cohort study

The EGALITY study: a confirmatory, randomized, double‐blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate‐to‐severe chronic plaque‐type psoriasis

Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)

The global state of psoriasis disease epidemiology: a workshop report

Reduction in skin cancer diagnosis, and overall cancer referrals, during the COVID‐19 pandemic

Psoriasis treat to target: defining outcomes in psoriasis using data from a real‐world, population‐based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR)

Clinical characteristics, symptoms and burden of psoriasis and atopic dermatitis in adults

Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta‐analysis of randomized controlled trials

Professor Lionel Fry (1933–2021)

A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 24‐week efficacy and safety results from a randomized, double‐blinded trial

Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double‐blinded, controlled studies (UNCOVER‐1, UNCOVER‐2, UNCOVER‐3)

Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up

Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study

The promise and challenges of cell therapy for psoriasis

The risk of malignancy in patients with secukinumab‐treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow‐up

Suchergebnisse filtern